# SCALOP-2

Source: https://onco.cc/trials/scalop-2/  
OnCo record `scalop-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SCALOP-2 is the UK follow-on to SCALOP, testing whether a higher radiotherapy dose or the HIV drug nelfinavir improves chemoradiotherapy for pancreatic cancer that cannot be removed; it finished in 2021 and its main results had not appeared in an indexed journal by September 2026.

## Summary

SCALOP-2 (ISRCTN50083238, NCT02024009) recruited 159 patients between 2016 and 2021 at 23 UK hospitals from Aberdeen to Colchester, led from the Churchill Cancer Centre in Oxford. After induction gemcitabine and nab-paclitaxel, patients were randomised between standard and high-dose capecitabine-based chemoradiotherapy with or without nelfinavir; the registry lists the trial as completed on 23 June 2021 with progression-free survival and overall survival as primary outcomes. No primary publication was found in Europe PMC on 24 September 2026, so the corpus records the design and status only; with LAP07 and CONKO-007 it is the evidence base for the locally advanced row's statement that chemoradiotherapy is optional.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-24
- Also known as: SCALOP 2
- Registry id: NCT02024009
- Phase: 1/2
- Setting: Locally advanced non-metastatic pancreatic cancer at 23 UK centres: induction gemcitabine plus nab-paclitaxel, then randomisation to capecitabine-based chemoradiotherapy at standard (50.4 Gy in 28 fractions) or high dose (60 Gy in 30 fractions), with or without the radiosensitiser nelfinavir, with progression-free survival and overall survival as the primary endpoints
- Sponsor: University of Oxford, with Cancer Research UK and Celgene
- Enrolled: 159

## Notes

- UK sites (registry, 23): Oxford (Churchill), Aberdeen, Clatterbridge, Belfast City, Bristol, Addenbrooke's Cambridge, Velindre Cardiff, Colchester and others.

## Sources

- ClinicalTrials.gov NCT02024009: https://clinicaltrials.gov/study/NCT02024009
- ISRCTN50083238: SCALOP-2: https://www.isrctn.com/ISRCTN50083238

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/)
- trials: [SCALOP](https://onco.cc/trials/scalop/)

---
JSON: https://onco.cc/api/v1/entities/scalop-2.json